Cystic Fibrosis Trust

AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders

Retrieved on: 
Thursday, September 14, 2023

AlveoGene has been created by OSE, Harrington and OCC in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC).

Key Points: 
  • AlveoGene has been created by OSE, Harrington and OCC in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC).
  • AlveoGene will also evaluate the potential of the InGenuiTy™ platform alongside other technologies to create a pipeline of novel inhaled gene therapies targeting other rare respiratory disease opportunities, such as lung surfactant deficiencies and idiopathic pulmonary fibrosis.
  • This will enable AlveoGene to rapidly advance our first candidate – AVG-001 a unique, inhaled gene therapy for AATD – towards clinical development.
  • AlveoGene is the culmination of a successful collaboration between leading researchers from top-ranked UK universities, via GTC, and we believe the company has the potential to become a leader in respiratory gene therapy.

Global $25 Billion CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 16, 2022

The "Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive insight on clinical and non-clinical factors that are driving the global CFTR Modulators market and its impact on the global pharmaceutical market landscape.
  • This drug class has grown considerably from 2012, with up to four agents available in the global market.
  • Global CFTR Modulators Market Opportunity: > USD 25 Billion
    Global CFTR Modulators Market Insights: Current, Regional, and Future Outlook 2028
    CFTR Modulators Availability By Dosage, Patent, and Price Analysis
    CFTR Modulators Clinical Trials Insight By Country, Company, and Phase: > 30 Drugs

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Retrieved on: 
Tuesday, October 19, 2021

The GTC is additionally contributing its knowledge in pre-clinical research and clinical gene therapy development.

Key Points: 
  • The GTC is additionally contributing its knowledge in pre-clinical research and clinical gene therapy development.
  • OXB is adding its leading competence in manufacturing lentiviral vector-based therapies to Boehringer Ingelheims expertise in the development of novel breakthrough therapies for respiratory diseases.
  • This partnership is central to our companys mission of delivering life changing gene therapies to patients and has the potential to provide a new therapeutic option for many cystic fibrosis patients globally.
  • David Ramsden, Chief Executive of the Cystic Fibrosis Trust said: It is great news that Boehringer Ingelheim have committed to the next stage of the development of a gene therapy treatment for people with cystic fibrosis.

Certilytics, Carewise Health to sponsor Cure CF golf tournament

Retrieved on: 
Thursday, July 22, 2021

LOUISVILLE, Ky., July 22, 2021 /PRNewswire/ -- Certilytics, Inc., and Carewise Health, Inc., are proud to be Diamond Sponsors of the 2021 Cure CF Classic, a golf tournament that will raise money for cystic fibrosis research and care.

Key Points: 
  • LOUISVILLE, Ky., July 22, 2021 /PRNewswire/ -- Certilytics, Inc., and Carewise Health, Inc., are proud to be Diamond Sponsors of the 2021 Cure CF Classic, a golf tournament that will raise money for cystic fibrosis research and care.
  • "The families who are part of Cure CF have seen firsthand the challenges that come with cystic fibrosis," said Joseph Klausing, executive director, Cure CF.
  • Through Certilytics' continued support of Cure CF, we are one day closer to CF standing for Cure Found."
  • Carewise Health, Inc. provides healthcare organizations with Care Management and Payment Integrity solutions that empower clinicians, patients, and health plans to achieve and sustain better health.

The Cystic Fibrosis Foundation Affirms Support of the Introduction of the PASTEUR Act

Retrieved on: 
Wednesday, June 16, 2021

Today, the Cystic Fibrosis Foundation affirmed its support for the PASTEUR Act, a bipartisan proposal that, if passed, will support the development of new antibiotics and promote appropriate use of existing ones.

Key Points: 
  • Today, the Cystic Fibrosis Foundation affirmed its support for the PASTEUR Act, a bipartisan proposal that, if passed, will support the development of new antibiotics and promote appropriate use of existing ones.
  • The Cystic Fibrosis Foundation applauds Senators Bennet and Young in reintroducing the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act.
  • The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis.
  • The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support.

First-of-Its-Kind Study Uses Smartphone to Track Cystic Fibrosis in Real Life

Retrieved on: 
Wednesday, June 2, 2021

The study will rely on observations that individuals living with cystic fibrosis make about their health in their daily lives to understand the impact of Trikafta when taken in the real world.

Key Points: 
  • The study will rely on observations that individuals living with cystic fibrosis make about their health in their daily lives to understand the impact of Trikafta when taken in the real world.
  • People ages 12 or older living with cystic fibrosis, who are taking Trikafta are eligible to participate.
  • The HERO-2 study is being conducted by Indiana University School of Medicine with funding from the Cystic Fibrosis Foundation.
  • The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis.

Hunterian Medicine Awarded Therapeutics Development Award from the Cystic Fibrosis Foundation

Retrieved on: 
Thursday, May 27, 2021

Hunterian Medicine LLC , a gene-editing and gene therapy company, has been awarded a Therapeutics Development Award by the Cystic Fibrosis Foundation .

Key Points: 
  • Hunterian Medicine LLC , a gene-editing and gene therapy company, has been awarded a Therapeutics Development Award by the Cystic Fibrosis Foundation .
  • "We are especially grateful to receive the Cystic Fibrosis Foundations support for our cystic fibrosis gene therapy program," said Dr. Vinny Jaskula-Ranga, President and CEO of Hunterian Medicine.
  • The vision behind the Path to a Cure initiative is just another example of what sets the Cystic Fibrosis Foundation apart."
  • As part of the award, Hunterian will collaborate with cystic fibrosis experts from the Johns Hopkins University School of Medicine and the Johns Hopkins Cystic Fibrosis Center.

Worldwide Cystic Fibrosis Industry to 2035 - Focus on US, Germany, France, Italy, Spain, UK and Japan - ResearchAndMarkets.com

Retrieved on: 
Monday, May 24, 2021

The "Global Cystic Fibrosis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cystic Fibrosis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • This research report provides Cystic Fibrosis epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Cystic Fibrosis patients, history of the disease at the population level (Cystic Fibrosis prevalence, Cystic Fibrosis incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Cystic Fibrosis patients by age group, gender
    The data from this research will help executives:
    Establish basis for Cystic Fibrosis market sizing, assessing market potential, and developing drug forecast models
    Identify Cystic Fibrosis patients segments through age groups, gender, and disease sub-types
    Evaluate Cystic Fibrosis market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005532/en/

Global Cystic Fibrosis Disease Insights and Market Forecasts Report 2020-2026: Sales and Patient Forecasts by Key Therapies - Trikafta, Pulmozyme, Kalydeco, Symdeko, MRT5005, Orkambi & ELX-02 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021

b'The "Cystic Fibrosis - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com\'s offering.\n"Cystic Fibrosis (CF): Disease Insights and Market Forecasts to 2026" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Cystic Fibrosis (CF) disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Cystic Fibrosis (CF), drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2026.\nThis section of the report gives the overview of Cystic Fibrosis (CF) disease indication in detail.

Key Points: 
  • b'The "Cystic Fibrosis - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com\'s offering.\n"Cystic Fibrosis (CF): Disease Insights and Market Forecasts to 2026" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Cystic Fibrosis (CF) disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Cystic Fibrosis (CF), drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2026.\nThis section of the report gives the overview of Cystic Fibrosis (CF) disease indication in detail.
  • The section highlights the basic definition, causes and symptoms of disease and details the types of Cystic Fibrosis (CF) disease.
  • Further details on the profile of Cystic Fibrosis (CF) patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report.
  • The report further highlights the multiple methods through which the patient can be diagnosed for Cystic Fibrosis (CF) disease.\nThis section of the report provides the overview of Cystic Fibrosis (CF) diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2018 till 2026.

Life Edit Therapeutics Announces Award from Cystic Fibrosis Foundation

Retrieved on: 
Tuesday, March 23, 2021

Life Edit Therapeutics Inc, a next generation gene-editing company, today announced that it has received an award from the Cystic Fibrosis Foundation to identify potential gene editing approaches to treat certain patients with cystic fibrosis (CF).

Key Points: 
  • Life Edit Therapeutics Inc, a next generation gene-editing company, today announced that it has received an award from the Cystic Fibrosis Foundation to identify potential gene editing approaches to treat certain patients with cystic fibrosis (CF).
  • This award is part of the Cystic Fibrosis Foundations Path to a Cure initiative that was launched in October 2019 to address and treat the underlying cause of CF.
  • As part of the $400,000 award from the Foundation, Life Edit will explore its large collection of adenine base editors, or A-base editors, that can potentially be used to correct the six most common, Class I, cystic fibrosis nonsense mutations to restore CFTR function in vivo.
  • As part of the agreement, Life Edit will benefit from materials, resources, and expertise from the Cystic Fibrosis Foundation.